Evidence map›Paper›PMID 40676263›Full record

ArticleNature cardiovascular research2025

The thrombin receptor PAR1 orchestrates changes in lymphatic endothelial cell junction morphology to augment lymphatic drainage during lung injury.

Chou Chou, Camila Ceballos Paredes, Barbara Summers, Jade Palmer-Johnson, Anjali Trivedi, Aneel Bhagwani, Kasper B Hansen, Anders S Kristensen, Stefka Gyoneva, Sharon A Swanger and 2 more

Abstract read
In one paragraph

Article in Nature cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Lung Lymphatics in Edema, Inflammation, and Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  4. Collecting lymphatics unzip to drain injured lungs.Nature cardiovascular research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chou ChouDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Camila Ceballos ParedesDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0009-0008-7471-2664
Barbara SummersDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Jade Palmer-JohnsonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Anjali TrivediDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Aneel BhagwaniDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Kasper B HansenDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3303-4819
Anders S KristensenDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8955-6790
Stefka GyonevaDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.
Sharon A SwangerDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0615-6244
Stephen F TraynelisDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.
Hasina Outtz ReedDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. hho2001@med.cornell.edu.ORCID http://orcid.org/0000-0001-8259-9616

Funding

Glutamate receptors and human neurological diseaseR35NS111619 · NINDS · EMORY UNIVERSITY · PI Stephen F Traynelis · 2019 to 2026
$6.6M
Multidisciplinary Approach Training in Respiratory ResearchT32HL134629 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Robert J Kaner, Heather Winona Stout Delgado · 2018 to 2026
$5.2M
Lymphatic Dysfunction in the Pathogenesis of COPDR01HL162990 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Hasina Outtz Reed · 2023 to 2026
$2.8M
NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORSR01NS039419 · NINDS · EMORY UNIVERSITY · PI TRAYNELIS, STEPHEN F. · 2000 to 2007
$2.6M
Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress SyndromeR01HL179084 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Hasina Outtz Reed · 2025 to 2026
$1.5M
NHLBI NIH HHS R01 HL162990NHLBI NIH HHS R01 HL179084NHLBI NIH HHS T32 HL134629NINDS NIH HHS R01 NS039419NINDS NIH HHS R35 NS111619U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS39419U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R35NS111619
6 · The paper itself

Abstract

The lung lymphatic vasculature is capable of remarkable increases in lymphatic drainage in settings of inflammation and edema; however, the mechanisms driving this are not clear. Here we show that lung injury transforms the configuration of lung lymphatic endothelial cell junctions from a continuous 'zippered' configuration to a discontinuous and permeable 'button' configuration. Despite similarity to the junctional changes often seen in leaky and dysfunctional blood vessels, we find that the shift to button junctions in the lymphatic vasculature has an opposite effect, resulting in augmented lung lymphatic drainage. Mechanistically, we demonstrate that lung lymphatic button junction formation in models of lung injury is dependent on the thrombin receptor protease-activated receptor 1, a known mediator of blood vessel permeability. These results uncover a previously unknown role for the thrombin receptor protease-activated receptor 1 in the lymphatic vasculature that promotes a similar change in junction morphology as seen in blood vessels, but with a disparate effect on lymphatic function.

Indexed as

Endothelial CellsIntercellular JunctionsLungLung InjuryLymphatic VesselsReceptor, PAR-1AnimalsCells, CulturedDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionReceptor, PAR-1

Identifiers

PMID40676263
PMCPMC12343296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.